Veracyte to Release Fourth Quarter and Full-Year 2021 Financial Results on February 28, 2022

Rhea-AI Summary

Veracyte, Inc. (Nasdaq: VCYT) will release its financial results for Q4 and full-year 2021 after market close on February 28, 2022. A conference call is scheduled at 4:30 p.m. ET to discuss these results and provide a general business update. Investors can access the conference call via the company's website, where a replay will also be available afterward. Veracyte is a diagnostics company focused on improving patient care through genomic tests for various cancers and diseases, leveraging advanced technology to expedite diagnosis and treatment.

Positive

• Upcoming release of Q4 and full-year 2021 financial results.
• Scheduled conference call to discuss financial results and business updates.
• Veracyte's expanding diagnostic test menu, enhancing patient care.

Negative

• None.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its full financial results for the fourth quarter and full-year 2021 after the close of market on Monday, February 28, 2022. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

The conference call will be webcast live from the company’s website and will be available via the following link: https://protect-us.mimecast.com/s/IyUzCADA4pUjMMGcmQqy2. A webcast replay will be available following conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.

The conference call can be accessed as follows:

U.S./Canada participant dial-in number (toll-free):		(855) 541-0980
International participant dial-in number:		(970) 315-0440
Conference I.D.:		5377945

About Veracyte

Veracyte, Inc. (Nasdaq: VCYT) is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of diagnostic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, colon cancer, and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its genomic tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220215005571/en/

Tracy Morris

Vice President of Corporate Communications & Investor Relations

tracy.morris@veracyte.com

650-380-4413

Source: Veracyte, Inc.

FAQ

When will Veracyte release its Q4 2021 financial results?

Veracyte will release its Q4 2021 financial results after market close on February 28, 2022.

What is the schedule for Veracyte's conference call?

Veracyte's conference call is scheduled for February 28, 2022, at 4:30 p.m. ET.

How can I access Veracyte's conference call?

The conference call can be accessed via Veracyte's website, and a replay will be available afterward.

What does Veracyte focus on in its business?

Veracyte focuses on providing genomic tests for diagnosing cancers and other diseases to improve patient care.